- Report
- June 2025
- 392 Pages
Global
From €4349EUR$4,950USD£3,752GBP
- Report
- March 2025
- 219 Pages
Global
From €4086EUR$4,650USD£3,524GBP
- Report
- May 2025
- 187 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- March 2025
- 250 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- July 2025
- 193 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- January 2025
- 123 Pages
Global
From €2635EUR$2,999USD£2,273GBP
- Report
- February 2025
- 219 Pages
Global
From €2197EUR$2,500USD£1,895GBP
- Report
- May 2025
- 142 Pages
Global
From €3471EUR$3,950USD£2,994GBP
- Report
- December 2024
- 150 Pages
Global
From €3471EUR$3,950USD£2,994GBP
- Report
- March 2025
- 67 Pages
Global
From €1713EUR$1,950USD£1,478GBP
- Report
- May 2025
- 191 Pages
Global
From €4349EUR$4,950USD£3,752GBP
- Report
- August 2024
- 72 Pages
United States
From €1098EUR$1,250USD£947GBP
- Report
- January 2025
- 126 Pages
Europe
From €2635EUR$2,999USD£2,273GBP
- Report
- June 2025
- 250 Pages
United States
From €2451EUR$2,789USD£2,114GBP
- Report
- June 2025
- 300 Pages
Europe
From €3400EUR$3,869USD£2,932GBP
- Report
- May 2025
- 96 Pages
Europe
From €3031EUR$3,450USD£2,615GBP
- Report
- May 2025
- 80 Pages
Africa, Middle East
From €2592EUR$2,950USD£2,236GBP
- Report
- May 2025
- 95 Pages
Asia Pacific
From €3031EUR$3,450USD£2,615GBP
- Report
- May 2025
- 87 Pages
North America
From €2592EUR$2,950USD£2,236GBP
- Report
- May 2025
- 172 Pages
Europe
From €3075EUR$3,500USD£2,653GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more